Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cara Therapeutics (CARA)
NASDAQ:CARA
Holding CARA?
Track your performance easily
CARA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.70 - $13.81
Previous CloseN/A
Volume26.15K
Average Volume (3M)240.36K
Market Cap
$27.38M
Enterprise Value$17.36M
Total Cash (Recent Filing)$58.28M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.67
Next Earnings
Feb 26, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-20.99
Shares Outstanding4,571,293
10 Day Avg. Volume72,760
30 Day Avg. Volume240,356
Standard Deviation0.22
R-Squared0.01
Alpha-0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.15
Price to Cash Flow (P/CF)-0.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.63
Enterprise Value/Revenue1.65
Enterprise Value/Gross Profit1.17
Enterprise Value/Ebitda-0.20
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Cara Therapeutics News
PremiumCompany Announcements
Cara Therapeutics Announces Merger with Tvardi Therapeutics
PremiumCompany Announcements
Cara Therapeutics Merges with Tvardi Therapeutics for STAT3 Focus
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CARA FAQ
What was Cara Therapeutics’s price range in the past 12 months?
Cara Therapeutics lowest stock price was $2.70 and its highest was $13.81 in the past 12 months.
What is Cara Therapeutics’s market cap?
Cara Therapeutics’s market cap is $27.38M.
When is Cara Therapeutics’s upcoming earnings report date?
Cara Therapeutics’s upcoming earnings report date is Feb 26, 2025 which is in 27 days.
How were Cara Therapeutics’s earnings last quarter?
Cara Therapeutics released its earnings results on Nov 04, 2024. The company reported -$0.228 earnings per share for the quarter, beating the consensus estimate of -$0.24 by $0.012.
Is Cara Therapeutics overvalued?
According to Wall Street analysts Cara Therapeutics’s price is currently Overvalued.
Does Cara Therapeutics pay dividends?
Cara Therapeutics does not currently pay dividends.
What is Cara Therapeutics’s EPS estimate?
Cara Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cara Therapeutics have?
Cara Therapeutics has 4,571,293 shares outstanding.
What happened to Cara Therapeutics’s price movement after its last earnings report?
Cara Therapeutics reported an EPS of -$0.228 in its last earnings report, beating expectations of -$0.24. Following the earnings report the stock price went down -1.685%.
Which hedge fund is a major shareholder of Cara Therapeutics?
Currently, no hedge funds are holding shares in CARA
---
Company Description
Cara Therapeutics
CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics. Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.
---
Technical Analysis
ACADIA Pharmaceuticals
―
BioMarin Pharmaceutical
―
Neurocrine
―
Vertex Pharmaceuticals
―
Amylyx Pharmaceuticals Inc
―
---